Pacira Pharmaceuticals (PCRX) AI Stock Analysis

• Market Cap: $861.62M
• Dividend Yield: N/A
• Average Volume (3M): 784.69K
• Price to Earnings (P/E): 135.5
• Beta (1Y): 0.89
• Revenue Growth: 3.14%
• EPS Growth: N/A
• Country: US
• Employees: 788
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.57
• Shares Outstanding: 40,489,895
• 10 Day Avg. Volume: 876,257
• 30 Day Avg. Volume: 784,686
• PEG Ratio: -0.40
• Price to Book (P/B): 1.66
• Price to Sales (P/S): 1.59
• P/FCF Ratio: 8.44
• Enterprise Value/Market Cap: 1.45
• Enterprise Value/Revenue: 1.72
• Enterprise Value/Gross Profit: 2.40
• Enterprise Value/Ebitda: 10.13
• 1Y Price Target: $30.00
• Price Target Upside: 35.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): 3.41
• Revenue Forecast (FY): $792.26M

• Rating: 67 Neutral
• Price Target: $23.00 ▲(4.07% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is driven primarily by solid underlying financial quality—especially the sharply improved leverage profile and strong, consistent cash generation—tempered by earnings volatility. Technicals are a notable drag given the stock trading below major moving averages, and valuation is also a headwind due to the very high P/E. The latest earnings call is supportive with upbeat guidance and operational/market-access progress, but elevated spending and near-term margin pressures cap upside.

Positive Factors

Balance sheet strength

A very low debt-to-equity ratio materially reduces financial risk and preserves strategic optionality. Durable low leverage improves the company’s ability to fund R&D, absorb reimbursements volatility, pursue partnerships or M&A, and sustain buybacks without relying on external financing.

Consistent cash generation

Consistent positive operating and free cash flow underpin long-term financial resilience. Reliable cash generation funds investment in commercial expansion, clinical programs, and share repurchases while insulating the business from short-term revenue swings and working-capital shocks.

Expanded market access & partnerships

Broad payer coverage and strategic partnerships (LG Chem, J&J MedTech) create durable commercial tailwinds. Expanded access increases addressable volume, while partnerships and planned ex-US commercialization diversify revenue streams and reduce single‑market concentration over multi-year horizons.

Negative Factors

Profitability volatility

Earnings have been inconsistent, with a sizable loss in 2024 and only a thin net margin in 2025. Persistent margin volatility undermines predictability of free cash flow, complicates funding plans for R&D and commercialization, and raises execution risk if revenue growth slows.

Rising operating expenses

Substantially higher R&D and SG&A spending increases fixed-cost burden and pressures margins unless revenue accelerates. If elevated spend persists, it could erode cash margins, limit flexibility for other investments, and require sustained top-line improvement to justify the stepped-up expense base.

Pipeline de-risking timeline

Key clinical programs are early stage and not powered for definitive efficacy, so near-term data will be exploratory. Meaningful de-risking and commercial impact will likely require larger Part B/registrational studies, delaying potential revenue contributions and keeping R&D spend as a downside.

Pacira Pharmaceuticals Business Overview & Revenue Model

Company Description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

How the Company Makes Money

Pacira Pharmaceuticals generates revenue primarily through the sales of its flagship product, EXPAREL, which is marketed to hospitals, surgical centers, and healthcare providers. The company also earns revenue from collaborations and partnerships with other pharmaceutical firms, which may include licensing agreements or co-development arrangements for its pipeline products. Additionally, Pacira may benefit from government reimbursements and healthcare insurance payments for its products, which are crucial for driving sales and expanding market access. The company has strategically focused on building relationships with healthcare professionals and institutions to promote the adoption of non-opioid pain management solutions, contributing to its overall revenue growth.

Pacira Pharmaceuticals Financial Statement Overview

Summary

Financials are anchored by a much stronger 2025 balance sheet (very low debt-to-equity near 0.01) and consistently positive operating/free cash flow with improved 2025 FCF. Offsetting this, profitability has been volatile (notably a 2024 net loss and thin ~3.7% net margin in 2025), keeping the score below the top tier.

Income Statement

Revenue has grown steadily over time, including strong growth in 2025 (annual revenue up meaningfully versus 2024). Profitability, however, has been volatile: 2024 swung to a sizable net loss after solid profitability in 2021–2023, and 2025 returned to a modest profit with a low net margin (~3.7%). Overall, the top-line trajectory is positive, but inconsistent earnings and margin variability keep the score in the middle range.

Balance Sheet

The balance sheet materially strengthened in 2025, with debt dropping to a very low level versus equity (debt-to-equity near 0.01), reducing financial risk and improving flexibility. Equity remains substantial, and returns on equity are positive again in 2025 after turning negative in 2024. The key watch-out is that this improvement follows a period of meaningfully higher leverage in prior years, so investors should confirm the durability of the lower-debt profile.

Cash Flow

Cash generation is a clear strength: operating cash flow and free cash flow have been consistently positive across the years provided, with 2025 free cash flow up strongly versus 2024. Cash flow quality is generally solid, with free cash flow tracking well relative to reported earnings in most years. A weakness is that cash flow coverage of reported profits has not been consistently strong (and was weaker in 2024), indicating periodic working-capital or non-cash impacts.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	726.41M	700.97M	674.98M	666.82M	541.53M
Gross Profit	519.37M	530.54M	490.31M	467.53M	401.28M
EBITDA	125.34M	29.12M	154.59M	140.38M	113.95M
Net Income	26.71M	-99.56M	41.95M	15.91M	41.98M
Balance Sheet
Total Assets	1.26B	1.55B	1.57B	1.68B	2.08B
Cash, Cash Equivalents and Short-Term Investments	158.54M	484.62M	278.58M	288.65M	656.41M
Total Debt	9.84M	638.85M	586.04M	763.39M	1.13B
Total Liabilities	571.81M	775.17M	704.26M	906.19M	1.34B
Stockholders Equity	693.11M	778.35M	870.13M	775.01M	730.41M
Cash Flow
Free Cash Flow	136.66M	178.75M	139.49M	115.20M	79.85M
Operating Cash Flow	151.99M	189.39M	154.65M	145.27M	125.72M
Investing Cash Flow	99.48M	-83.28M	77.54M	-225.19M	-20.79M
Financing Cash Flow	-369.63M	17.36M	-183.03M	-401.53M	380.69M

Pacira Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 22.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCRX, the sentiment is Negative. The current price of 22.1 is above the 20-day moving average (MA) of 21.97, below the 50-day MA of 22.80, and below the 200-day MA of 23.90, indicating a bearish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 41.93 is Neutral, neither overbought nor oversold. The STOCH value of 37.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PCRX.

Pacira Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PCRX	67 Neutral	$861.62M	135.46	0.96%	―	3.14%	―
ANIP	67 Neutral	$1.69B	22.44	15.11%	―	48.87%	―
COLL	62 Neutral	$1.32B	24.23	23.70%	―	26.34%	-32.79%
SUPN	60 Neutral	$3.16B	-80.55	-3.68%	―	4.54%	-130.59%
AMPH	60 Neutral	$953.23M	10.33	12.90%	―	-0.03%	-27.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Pacira Pharmaceuticals Corporate Events

Pacira BioSciences adds seasoned leader to board

On January 27, 2026, Pacira BioSciences expanded its Board of Directors from nine to 10 members and appointed veteran biopharmaceutical executive Samit Hirawat, M.D., as a Class III director and member of the Science and Technology Committee, with the appointment announced publicly on January 28, 2026. The addition of Hirawat, an independent director with more than 25 years of clinical development and leadership experience at Bristol Myers Squibb and Novartis, underscores Pacira’s efforts to strengthen its governance and scientific oversight as it seeks to accelerate growth of its non-opioid pain portfolio and advance its pipeline, including next-generation gene therapies, potentially bolstering its competitive position in the non-opioid pain management market.

The most recent analyst rating on (PCRX) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.